Primary endpoint objective
RAP, myocardial ischemia
MYOCARDIAL ISCHEMIA
The primary objective of this study is the effect of SCS in patients with RAP measured by the change in the percentage of myocardial ischemia (% of the left ventricular myocardium) using myocardial perfusion PET scan at the end of the six‐month period of treatment with SCS compared with baseline.